In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles

被引:40
作者
Boiani, Lucia [1 ]
Gerpe, Alejandra [1 ]
Aran, Vicente J. [2 ]
Torres de Ortiz, Susana [3 ]
Serna, Elva [3 ]
Vera de Bilbao, Ninfa [3 ]
Sanabria, Luis [3 ]
Yaluff, Gloria [3 ]
Nakayama, Hector [3 ]
Rojas de Arias, Antonieta [3 ]
Diego Maya, Juan [4 ]
Antonio Morello, J. [4 ]
Cerecetto, Hugo [1 ]
Gonzalez, Mercedes [1 ]
机构
[1] Univ Republica, Fac Quim, Fac Ciencias, Dept Quim Organ, Montevideo 11400, Uruguay
[2] CSIC, Inst Quim Med, E-28006 Madrid, Spain
[3] Univ Nacl Asuncion, Dept Trop Med, Inst Invest Ciencias Salud, Asuncion, Paraguay
[4] Univ Chile, ICBM, Fac Med, Santiago, Chile
关键词
Nitroindazoles; Chagas' disease; Leishmaniasis; Therapy; TRYPANOSOMA-CRUZI; DERIVATIVES; LEISHMANIASIS; CHEMOTHERAPY; AGENTS; ANALOGS; DRUGS;
D O I
10.1016/j.ejmech.2008.06.024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously, we have identified a series of 5-nitroindazoles with good antiprotozoal activities, against Trypanosoma cruzi epimastigotes and Trichomonas vaginalis. Most of them have shown very low unspecific toxicity on macrophage cell lines. In the present work, we assayed these compounds on T. cruzi bloodstream trypomastigotes and Leishmania promastigotes (Leishmania amazonensis, Leishmania braziliensis and Leishmania infantum). Derivatives 1, 2, 7 and 8 displayed remarkable trypanocidal activity (>80% lysis) equivalent to gentian violet. Derivatives 2 and 10, as Pentamidine, caused the complete lysis of promastigotes of Leishmania. An oxidative stress-mediated mechanism of action was confirmed for derivatives 1, 10 and 12 on T. cruzi epimastigotes. Supported by the in vitro activities, derivatives 1 and 2 were submitted to in vivo assays using an acute model of Chagas' disease and a short-term treatment. None of the animals treated with derivatives 1 and 2 died, unlike the untreated control and Benznidazole groups. (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1034 / 1040
页数:7
相关论文
共 20 条
[1]   Synthesis and biological properties of new 5-nitroindazole derivatives [J].
Arán, VJ ;
Ochoa, C ;
Boiani, L ;
Buccino, P ;
Cerecetto, H ;
Gerpe, A ;
González, M ;
Montero, D ;
Nogal, JJ ;
Gómez-Barrio, A ;
Azqueta, A ;
de Ceráin, AL ;
Piro, OE ;
Castellano, EE .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (09) :3197-3207
[2]   2H-benzimidazole 1,3-dioxide derivatives:: A new family of water-soluble anti-trypanosomatid agents [J].
Boiani, Mariana ;
Boiani, Lucia ;
Denicola, Ana ;
Torres de Ortiz, Susana ;
Serna, Elva ;
Vera de Bilbao, Ninfa ;
Sanabria, Luis ;
Yaluff, Gloria ;
Nakayama, Hector ;
Rojas de Arias, Antonieta ;
Vega, Celeste ;
Rolan, Miriam ;
Gomez-Barrio, Alicia ;
Cerecetto, Hugo ;
Gonzalez, Mercedes .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) :3215-3224
[3]   Pharmacological properties of indazole derivatives:: Recent developments [J].
Cerecetto, H ;
Gerpe, A ;
González, M ;
Arán, VJ ;
de Ocáriz, CO .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (10) :869-878
[4]  
CERECETTO H, 2002, CURR TOP MED CHEM, V2, P1185
[5]   Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis [J].
Chiari, E ;
Oliveira, AB ;
Prado, MAF ;
Alves, RJ ;
Galvao, LMC ;
Araujo, FG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :613-615
[6]   Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs [J].
Croft, SL ;
Coombs, GH .
TRENDS IN PARASITOLOGY, 2003, 19 (11) :502-508
[7]   Chemotherapy of leishmaniasis [J].
Croft, SL ;
Yardley, V .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (04) :319-342
[8]   Antiprotozoal activities of phospholipid analogues [J].
Croft, SL ;
Seifert, K ;
Duchêne, M .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2003, 126 (02) :165-172
[9]  
DOCAMPO R, 1986, FED PROC, V45, P2471